Naar homepage     
Chronische Cerebro-Spinale Veneuze Insufficiëntie
Aanmelden op het CCSVI.nl forum
Lees Voor (ReadSpeaker)    A-   A+
Over CCSVI.nl | Zoeken | Contact | Forum
CCSVI.nl is onderdeel van de
Franz Schelling Website
meer informatie
  
Thursday, October 18, 2012 9:13 PM | CCSVI Toronto Volg link

Continues to discuss the new "rejection" for "Zamboni method" arrived in recent days as a result of recent studies presented at ECTRIMS congress in Lyon. Data from the multicenter study... continues to discuss the new "rejection" for "Zamboni method" arrived in recent days as a result of recent studies presented at ECTRIMS congress in Lyon. Data from the multicenter study "Cosmo", sponsored and funded by the Italian Multiple Sclerosis Association (AISM) and its Foundation, the IMF, would show it as 97% of patients do not present the problem to the veins, and how therefore there is no no reason why people with multiple sclerosis to undergo tests for the diagnosis of CCSVI (chronic cerebrospinal venous insufficiency).

At this point the Steering Committee of the study Brave Dreams (acronym for Brain venous drainage exploited against multiple sclerosis, which means "to take advantage of the venous drainage of multiple sclerosis," funded by the Emilia Romagna) has assessed whether the scientific and ethical reasons, that have led to the initiation of the study, are still present, in the light of new scientific information. Was assessed at the end of not having to stop the recruitment of patients, while placing two important questions: What level of uncertainty exists about the role of CCSVI in causal mechanisms and clinical course of Sm and if there is still a public health problem in the fact that patients with Sm seek and obtain diagnostic procedures and operations angioplasty although there is sufficient evidence on safety and effectiveness. On the first question, the Steering Committee considered that there is still a lack of homogeneity in the different studies and the study Brave Dreams can bring new and stronger evidence in this area. Regarding the second question, the Steering Committee has decided to take steps to verify that they are currently the frequency of use in the public and private sectors, of angioplasties in patients with Sm, through appropriate contacts with the Ministry and the Regions.

October 17 2012

Translated from:

http://lanuovaferrara.gelocal.it/cronaca/2012/10/17/news/il-comitato-guida-lo-studio-deve-andare-avanti-1.5881156